| Ytd | 158.28% | |
| 1y | 39.78% |
| Open | Prev Close | 3.90 | Low | High | Mkt Cap | 301.03M | |||
| Vol | 0.00 | Avg Vol | 1.53M | EPS | -0.77 | P/E | N/A | Forward P/E | -3.49 |
| Beta | 0.77 | Short Ratio | 0.75 | Inst. Own | 42.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 3.72 | 200-d Avg | 2.78 | 1yr Est | 12.50 |
ELDN News
The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-
Eledon has established the regulatory framework for its Phase 3 kidney transplantation program and p
AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cel
Tegoprubart-treated patients maintained higher mean eGFR over time, including a statistically signif
Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated results from a
Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that updated results f
NewcelX submitted an FDA Pre-IND package for NCEL-101 to advance its type 1 diabetes treatment into
Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.33) per share which missed the analyst
https://www.sec.gov/Archives/edgar/data/1404281/000119312526201426/d79008ds3.htm
NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and pl
NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine comp
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.10) per share which beat the analyst co
Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated results from a
The collaboration is designed to advance combination strategies integrating NewcelX's lead progr
Data from eight participants continue to support safety and tolerability profile of tegoprubartMean
Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN) today announced a summary of 2025 acc
On Tuesday, 56 companies set new 52-week lows.
During Wednesday's session, 212 companies made new 52-week lows.
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings
On Wednesday, 220 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quart
Thursday's session saw 337 companies set new 52-week lows.
On Wednesday, 479 stocks made new 52-week lows.
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarte
Here's a roundup of top developments in the biotech space over the last 24 hours:
Gainers Creatd, Inc. (NASDAQ: CRTD) shares jumped 58.5% to close at $1.28 on Thursday. Creatd’s b
Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report
On Tuesday, 242 companies hit new 52-week lows.
On Monday, 524 stocks hit new 52-week lows.
Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report
Stocks That Hit 52-Week Lows On Monday Monday morning, 285 companies reached new 52-week lows.
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report